Table 2.

In vitro susceptibilities of Candida and Aspergillus spp. to CD101 as determined by 24 h CLSI and EUCAST BMD methods using prominent (≥50%) MIC endpoint criteria

Species (no. tested)	Test method	CD101 MIC or MEC (mg/L)		Percentage EA
		range	mode
C. albicans (25)	CLSI	≤0.008–1	0.015	92.0
	EUCAST	≤0.008–1	≤0.008
C. glabrata (25)	CLSI	0.015–2	0.06	100.0
	EUCAST	≤0.008–2	0.06
C. tropicalis (21)	CLSI	≤0.008–1	0.015	100.0
	EUCAST	≤0.008–0.5	0.03
C. krusei (20)	CLSI	0.015–1	0.06	100.0
	EUCAST	0.03–0.5	0.06
C. parapsilosis (15)	CLSI	0.5–2	1	100.0
	EUCAST	0.5–1	1
A. fumigatus (20)	CLSI	≤0.008–0.06	≤0.008	95.0
	EUCAST	≤0.008–0.03	0.015
A. terreus (19)	CLSI	≤0.008–0.03	≤0.008	100.0
	EUCAST	≤0.008–0.03	≤0.008
A. flavus (12)	CLSI	≤0.008–0.015	≤0.008	100.0
	EUCAST	≤0.008–0.03	≤0.008
A. niger (16)	CLSI	≤0.008–0.03	≤0.008	100.0
	EUCAST	≤0.008–0.03	≤0.008